Compare Medline Inc. Class A Common Stock (MDLN) vs Toro Company (The) Common Stock (TTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medline Inc. Class A Common Stock vs Toro Company (The) Common Stock — how do they compare? Medline Inc. Class A Common Stock trades at $35.85 (market cap $31.32B), while Toro Company (The) Common Stock trades at $98.27 (market cap $9.27B). The key difference: Medline Inc. Class A Common Stock is far larger — about 3.4× Toro Company (The) Common Stock's market cap, and Toro Company (The) Common Stock pays a 1.59% dividend while Medline Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medline Inc. Class A Common Stock for 6 Days and Toro Company (The) Common Stock for 0 Days on average.
| MDLN | TTC | |
|---|---|---|
Market Cap | $31.32B | $9.27B |
Volume | 4,364,703 | 688,325 |
Sector | Health | Industrials |
52-Week High | $49.99 | $101.76 |
52-Week Low | $31.64 | $67.99 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $41.28B | $10.17B |
Dividend Yield | — | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medline (MDLN) trades at $35.70, down 0.17% with a bullish technical outlook despite recent volatility. The company shows strong revenue growth with $28.43B in 2025 and improved earnings beats in Q1-Q2 2026. However, multiple securities fraud investigations related to product quality issues and a 13% stock drop in October 2026 create significant headwinds. Analyst consensus remains strongly bullish with 88% buy ratings and a $44.11 price target, representing 23.6% upside potential from current levels.
MDLN presents a high-risk, high-reward opportunity with strong fundamentals offset by legal uncertainties. The stock's valuation appears reasonable with P/E of 44.66 and P/S of 1.05, while technical indicators suggest near-term support at $35. Key risks include ongoing fraud investigations and potential legal liabilities that could impact future performance despite positive earnings momentum.
Toro Company (TTC) trades at $97.88, up 1.27% with strong technical momentum above its 50-day moving average. The company demonstrates solid fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.33 beating expectations of $1.31, and raised full-year guidance. Revenue growth of 8.4% in Q3 2026 to $1.23 billion reflects robust demand across professional and residential segments, supported by infrastructure and automation initiatives under new CEO leadership.
Toro presents a balanced investment case with 36% analyst buy ratings and $117.50 price target suggesting 20% upside. However, execution risks from inflation, tariffs, and competitive pressures warrant caution. The stock's premium valuation (P/E 26.17) requires sustained earnings growth, making Q3 2026 results critical for validating current momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medline Inc. Class A Common Stock
Medline provides medical-surgical products and supply-chain solutions for healthcare providers. Its portfolio and distribution network serve hospitals, clinics, long-term care facilities, and other care settings.
Read more on MDLN →About Toro Company (The) Common Stock
The Toro Company designs, manufactures, and markets equipment for turf maintenance, snow and ice management, landscaping, construction, and irrigation. Its products serve golf courses, sports fields, and residential and commercial properties in more than 125 countries.
Read more on TTC →
